[Sar9,Met(O2)11]-Substance P

Name: [Sar9,Met(O2)11]-Substance P
Brand: MedChemExpress
SKU: HY-P1012
Rating: 4.5 (1 reviews)

Cat. No.: HY-P1012 Purity: 98.84%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

[Sar9,Met(O2)11]-Substance P is a tachykinin NK₁ receptor selective agonist.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

[Sar9,Met(O2)11]-Substance P Chemical Structure

CAS No. : 110880-55-2

Size	Price	Stock	Quantity
1 mg	USD 96	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 348	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 624	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1320	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of [Sar9,Met(O2)11]-Substance P:

[Sar9,Met(O2)11]-Substance P TFA In-stock

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

[Sar9,Met(O2)11]-Substance P is a tachykinin NK₁ receptor selective agonist.

IC₅₀ & Target

NK₁ receptor^[1]

In Vitro

[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissimilar time-course. Both agonists increase dose-dependently face washing and sniffing while [Sar9,Met(O2)11]-Substance P is the sole to produce grooming^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1393.66

Formula

C₆₄H₁₀₀N₁₈O₁₅S

CAS No.

110880-55-2

Appearance

Solid

Color

White to off-white

Sequence

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-{Sar}-Leu-{Met[O2]}-NH2

Sequence Shortening

RPKPQQFF-{Sar}-L-{Met[O2]}-NH2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (71.75 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.7175 mL	3.5877 mL	7.1754 mL
5 mM	0.1435 mL	0.7175 mL	1.4351 mL
10 mM	0.0718 mL	0.3588 mL	0.7175 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (71.75 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 98.84%

Select Batch:

Data Sheet (278 KB) SDS (252 KB)

COA (253 KB) LCMS (89 KB) Elemental Analysis Report (113 KB)

Handling Instructions (2659 KB)

References

[1]. Cellier E, et al. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br J Pharmacol. 1999 Jun;127(3):717-28. [Content Brief]

Kinase Assay
^[1]

Rats initially receive an i.c.v. injection of artificial cerebrospinal fluid (aCSF; 1 μl) followed 60 min later by a single dose of either [Sar9,Met(O2)11]-Substance P (10 pmol (n=9), 25 pmol (n=9), 65 pmol (n=8) or 100 pmol (n=8)) or septide (10 pmol (n=12), 25 pmol (n=9), 65 pmol (n=6) or 100 pmol (n=6)) to construct a complete dose-response curve. Each rat is selected randomly and injected with only one of the two agonists for the remainder of the protocol. Increasing doses of [Sar9,Met(O2)11]-Substance P or septide are given at 24 h intervals on day 1 (10 pmol), day 2 (25 pmol), day 3 (65 pmol) and day 4 (100 pmol). Control rats (n=18) receive only the vehicle (aCSF) each day of experiment. Peptides are administered in a volume of 1 μL of vehicle followed by 5 μL flush volume of aCSF which corresponds to the void volume of the catheter. Each dose is calculated per rat in 1 μL solution^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Cellier E, et al. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br J Pharmacol. 1999 Jun;127(3):717-28. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.7175 mL	3.5877 mL	7.1754 mL	17.9384 mL
	5 mM	0.1435 mL	0.7175 mL	1.4351 mL	3.5877 mL
	10 mM	0.0718 mL	0.3588 mL	0.7175 mL	1.7938 mL
	15 mM	0.0478 mL	0.2392 mL	0.4784 mL	1.1959 mL
	20 mM	0.0359 mL	0.1794 mL	0.3588 mL	0.8969 mL
	25 mM	0.0287 mL	0.1435 mL	0.2870 mL	0.7175 mL
	30 mM	0.0239 mL	0.1196 mL	0.2392 mL	0.5979 mL
	40 mM	0.0179 mL	0.0897 mL	0.1794 mL	0.4485 mL
	50 mM	0.0144 mL	0.0718 mL	0.1435 mL	0.3588 mL
	60 mM	0.0120 mL	0.0598 mL	0.1196 mL	0.2990 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.